1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,143 | 0,154 | 13:15 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.07. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 26.06. | VIVA BIOTECH (01873): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026 | 1 | HKEx | ||
| 25.06. | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT GRANT OF RESTRICTED SHARE UNITS | - | HKEx | ||
| 25.06. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 18.06. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 10.06. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 03.06. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 27.05. | Viva Biotech: From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery | 618 | PR Newswire | SHANGHAI, May 27, 2026 /PRNewswire/ -- On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated... ► Artikel lesen | |
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 26.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 18.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 4 | HKEx | ||
| 08.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 22.04. | VIVA BIOTECH (01873): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 1 | HKEx | ||
| 22.04. | VIVA BIOTECH (01873): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | - | HKEx | ||
| 22.04. | VIVA BIOTECH (01873): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 22.04. | VIVA BIOTECH (01873): PROPOSED RE-ELECTION OF RETIRING DIRECTORS PROPOSED RE-APPOINTMENT OF AUDITOR PROPOSALS FOR GRANTING OF GENERAL MANDATES TO ISSUE ... | - | HKEx | ||
| 22.04. | VIVA BIOTECH (01873): 2025 ANNUAL REPORT | 1 | HKEx | ||
| 07.04. | Fifteen Years Alongside Europe's Drug Discovery Teams: Viva Biotech Strengthens Continuity from Discovery to Development and Manufacturing | 599 | PR Newswire | Delivering Continuity in a Changing LandscapeClients across the region view Viva Biotech not just as a service provider, but as a consistent, reliable partner and collaborator, an extension of their... ► Artikel lesen | |
| 30.03. | Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up | 391 | PR Newswire | CRO Business Sustained Recovery in Growth, AI-Enabled Drug Discovery Technology Maintained Industry-Leading AdvantagesThroughout 2025, revenue from the Company's CRO business rose from RMB810.9 million... ► Artikel lesen | |
| 30.03. | Viva Biotech Holdings Full Year Profit Climbs | 2 | RTTNews | ||
| 30.03. | VIVA BIOTECH (01873): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | - | HKEx |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,140 | +0,09 % | Valneva ÜBERRASCHT Anleger: Was hinter dem Kursanstieg wirklich steckt - Was das für Ihr Depot bedeutet! | ||
| NOVONESIS | 56,10 | -0,46 % | Novonesis Q1 Net Profit Rises, Net Sales Up 7% Organically; Backs FY26 Outlook | BRUSSELS (dpa-AFX) - Novonesis A/S (NVZMF.PK, NSIS_B.CO, NSIS-B.CO, NVZMF, NSIS-B) Tuesday said that its first quarter net profit rose from last year, helped by good performances by the Food... ► Artikel lesen | |
| GENMAB | 245,10 | +1,20 % | Genmab Reports Q2 Worldwide Net Trade Sales Of DARZALEX | NEW BRUNSWICK (dpa-AFX) - Genmab A/S (GMAB) announced that worldwide net trade sales of DARZALEX, including sales
of the subcutaneous product, as reported by J&J were $4.207 billion in the... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,940 | +1,81 % | Arbutus, Genevant File International Lawsuits Against Pfizer, BioNTech | NEW YORK CITY (dpa-AFX) - Arbutus Biopharma (ABUS), and its licensee, Genevant Sciences - a unit of Roivant Sciences (ROIV)), announced the filing of three international lawsuits seeking to... ► Artikel lesen | |
| BEONE MEDICINES LTD ADR | 280,00 | +2,94 % | BEONE MEDICINES (06160): DATE OF SECOND QUARTER 2026 FINANCIAL RESULTS ANNOUNCEMENT AND NOTICE OF AUDIT COMMITTEE ACTION | ||
| MUSTGROW BIOLOGICS | 0,210 | 0,00 % | Die Zukunft der Ernährung: Große Chancen für MustGrow und K+S! Wie geht es nach dem Absturz bei Evotec weiter? | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Die globale Lebensmittelversorgung steht vor einem tiefgreifenden Wandel. Eine wachsende Weltbevölkerung, die Erderwärmung und strengere... ► Artikel lesen | |
| SINO BIOPHARM | 0,581 | +1,38 % | SBP GROUP (01177): VOLUNTARY ANNOUNCEMENT - TRD205 "AT2R ANTAGONIST" GRANTED THE CDE'S BREAKTHROUGH THERAPY DESIGNATION | ||
| VERICEL | 42,200 | +4,98 % | Vericel Corporation: Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026 | ||
| MOLECULIN BIOTECH | 2,150 | +0,47 % | Moleculin Biotech, Inc.: Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment | Access the segment here HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive... ► Artikel lesen | |
| FAETH THERAPEUTICS | 27,960 | -0,82 % | Citizens initiates Faeth Therapeutics stock at outperform, $51 target | ||
| ZAI LAB LTD ADR | 17,700 | -1,12 % | Zai Lab Limited: Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas | Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,818 | +7,07 % | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia... ► Artikel lesen | |
| REGENXBIO | 9,518 | +5,33 % | Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments | ||
| ZEVRA THERAPEUTICS | 10,750 | +1,90 % | Zevra Therapeutics Announces Publication of Positive MIPLYFFA Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC) | BOSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living... ► Artikel lesen | |
| AKEBIA | 1,093 | -4,17 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Strengthens Vafseo (vadadustat) Patent Portfolio | CAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen |
VIVA BIOTECH HOLDINGS gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,143 Euro und damit +4,38 % im Plus. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVA BIOTECH HOLDINGS finden Sie auf Wallstreet Online.